Table 3.
Description of serious adverse events (SAEs)
| CT | TT | ICI | Overall n=293 |
||||
| SARS-CoV-2 negative n=37 |
SARS-CoV-2 positive n=13 |
SARS-CoV-2 negative n=60 | SARS-CoV-2 positive n=24 |
SARS-CoV-2 negative n=107 |
SARS-CoV-2 positive n=52 | ||
| Hospitalizations: | |||||||
| Yes | 0 | 1 (7.7) | – | – | 2 (1.9) | 7 (13.5) | 10 (3.4) |
| Number of deaths | – | 1 (100.0) | 0 (0.0) | 4 (57.1) | 5 (50.0) | ||
| Reasons for hospitalization: | |||||||
| Patients with radiographic changes, n (%) | – | 0 (0.0) | 0 (0.0) | 7 (100.0) | 7 (70.0) | ||
| Patients requiring oxygen, n (%) | – | 1 (100.0) | 0 (0.0) | 5 (71.4) | 6 (60.0) | ||
| Patients requiring renal replacement therapy, n (%) | – | 0 (0.0) | 0 (0.0) | 1 (14.3) | 1 (10.0) | ||
| Patients requiring antibiotics therapy, n (%) | – | 1 (100.0) | 0 (0.0) | 6 (85.7) | 7 (70.0) | ||
| Patients requiring antivirals therapy, n (%) | – | 0 (0.0) | 0 (0.0) | 3 (50.0) | 3 (33.3) | ||
| Missing | – | 0 | 0 | 1 | 1 | ||
| Patients requiring glucocorticoids therapy, n (%) | – | 0 (0.0) | 0 (0.0) | 2 (33.3) | 2 (22.2) | ||
| Missing | – | 0 | 0 | 1 | 1 | ||
| Patients requiring anti-IL6 therapy, n (%) | – | 0 (0.0) | 0 (0.0) | 2 (33.3) | 2 (22.2) | ||
| Missing | – | 0 | 0 | 1 | 1 | ||
| Number of deaths, n (%) | 1 (2.6) | 2 (15.4) | – | – | 2 (1.9) | 6 (11.5) | 11 (3.8) |
SARS-CoV-2 positive: one positive result from serologic test confirmed by nasal swab.
CT, chemotherapy; ICI, immune checkpoint inhibitors; TT, targeted therapy.